Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alpha-gal epitope (galactose-α-1,3-galactose, or α-Gal) is a carbohydrate structure found on glycoproteins and glycolipids of most mammals except for humans, apes, and Old World monkeys. In humans, the immune response to this epitope is mediated by pre-existing anti-α-Gal antibodies (IgM, IgA, IgG), which can trigger allergic reactions to mammalian-derived products or cause hyperacute rejection of xenografts. Sensitization to alpha-gal through tick bites can induce class-switching to IgE, resulting in alpha-gal syndrome (AGS), a delayed food allergy. However, anti-α-Gal antibodies also contribute to defense against pathogens expressing the α-Gal epitope.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-gal epitope-mediated immune response.